Eris Lifesciences and Natco Ties Up for Semaglutide Rollout

Eris Lifesciences has announced a partnership with Natco Pharma for the commercialization of semaglutide in India, strengthening its footprint in the fast-growing diabetes and obesity treatment market.

The agreement comes as the patent on semaglutide, the key ingredient in Novo Nordisk’s blockbuster drugs Wegovy and Ozempic, is set to expire in certain markets, including India, this March.

Semaglutide is a GLP-1 receptor agonist widely used for managing type 2 diabetes and weight loss. With the patent expiry nearing, several Indian drugmakers such as Dr Reddy’s Laboratories, Lupin, Cipla, and Sun Pharma are preparing to introduce generic versions. The entry of semaglutide is expected to intensify competition in the domestic market.

Also Read: How Digital Maturity is Powering Pharma's GMP Evolution

The ?2,894-crore Eris Lifesciences has steadily built a strong presence in diabetology. The addition of semaglutide is seen as a strategic move to deepen its diabetes portfolio and tap into rising demand for advanced therapies. Under the collaboration, Natco Pharma will leverage its expertise in manufacturing and regulatory approvals for complex formulations, while Eris will drive commercialization through its established sales network in chronic therapies.

Natco Pharma has already secured regulatory approval in India, clearing the path for a launch in March 2026. Amit Bakshi, Eris Lifesciences Chairman and Managing Director, said, “This partnership reflects our continued commitment to strengthening our diabetes franchise with innovative and high-impact therapies. With our strong commercial infrastructure and deep engagement in chronic therapies…Eris is well positioned to drive rapid adoption and enhance patient access in India.”